You have free access to this content

Cancer

Cover image for Cancer

15 November 2009

Volume 115, Issue 22

Pages 5129–5361

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Commentary

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. You have free access to this content
      The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula : A retrospective study (pages 5132–5138)

      Yang Yu, Qingbo Lang, Zhe Chen, Bai Li, Chaoqin Yu, Dezeng Zhu, Xiaofeng Zhai and Changquan Ling

      Article first published online: 11 AUG 2009 | DOI: 10.1002/cncr.24567

      In a study using JDF granule preparation (a traditional Chinese herbal medicine formula), it was found that combining transcatheter arterial chemoembolization with Chinese herbal medications may prolong survival in patients with unresectable hepatocellular carcinoma.

      Corrected by:

      Communication: Notice of duplicate publication

      Vol. 118, Issue 2, 292, Article first published online: 5 JAN 2012

  3. Editorial

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. You have free access to this content
      Perioperative chemotherapy for urothelial cancer : How have we made a “sow's ear” out of a chemotherapy-sensitive tumor? (pages 5139–5142)

      Tanya B. Dorff and David I. Quinn

      Article first published online: 30 JUL 2009 | DOI: 10.1002/cncr.24569

      Urothelial cancer is very responsive to chemotherapy. The deficit in translating this into improved patient outcome is a major blight on contemporary practice in urologic oncology.

  4. Review Article

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. You have free access to this content
      Maintenance therapy in nonsmall-cell lung cancer : A new treatment paradigm (pages 5143–5154)

      Tony S. K. Mok and Suresh S. Ramalingam

      Article first published online: 5 AUG 2009 | DOI: 10.1002/cncr.24563

      The aim of this review was to describe the concept of maintenance therapy and discuss the emergence of this new treatment paradigm in advanced nonsmall-cell lung cancer.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years : A GET(N)A Working Group analysis (pages 5155–5165)

      Rémy Largillier, Alexia Savignoni, Joseph Gligorov, Philippe Chollet, Marie-Noëlle Guilhaume, Marc Spielmann, Elisabeth Luporsi, Bernard Asselain, Bruno Coudert, Moïse Namer and on behalf of the GET(N)A Group

      Article first published online: 18 AUG 2009 | DOI: 10.1002/cncr.24608

      In women aged younger than 35 years, a pregnancy occurring before or after the diagnosis of breast cancer was not an independent prognostic factor of death. In the subset of patients having a high risk of relapse, it may be preferable to postpone a pregnancy beyond 5 years after the breast cancer therapy.

    2. You have free access to this content
      Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients (pages 5166–5174)

      Kathryn A. Phillips, Deborah A. Marshall, Jennifer S. Haas, Elena B. Elkin, Su-Ying Liang, Michael J. Hassett, Ilia Ferrusi, Jane E. Brock and Stephanie L. Van Bebber

      Article first published online: 14 SEP 2009 | DOI: 10.1002/cncr.24574

      The authors found little evidence about the clinical use and cost effectiveness of human epidermal growth receptor 2 testing for breast cancer patients in the adjuvant setting. Given the increasing use of targeted therapies, it is critical to build an evidence base that supports making informed decisions on emerging testing technologies in clinical practice.

    3. Gastrointestinal Disease
      You have free access to this content
      Multimodality therapy for locoregional extrahepatic cholangiocarcinoma : A population-based analysis (pages 5175–5183)

      Clifton D. Fuller, Samuel J. Wang, Mehee Choi, Brian G. Czito, John Cornell, Tania M. Welzel, Katherine A. McGlynn, Join Y. Luh and Charles R. Thomas Jr

      Article first published online: 27 JUL 2009 | DOI: 10.1002/cncr.24572

      Evaluation of survival outcomes for extrahepatic cholangiocarcinoma using parametric survival analysis for cases extracted from the Surveillance, Epidemiology, and End Results data set suggested that multimodality therapy including surgery and adjuvant radiotherapy is associated with early survival improvement.

    4. You have free access to this content
      The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma (pages 5184–5192)

      Heta Javeri, Lianchun Xiao, Eric Rohren, Jeffrey H. Lee, Zhongxing Liao, Wayne Hofstetter, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Homer Macapinlac, Xuemei Wang and Jaffer A. Ajani

      Article first published online: 14 AUG 2009 | DOI: 10.1002/cncr.24604

      The authors assessed 151 consecutive patients with gastroesophageal adenocarcinoma who had chemoradiation and surgery. Baseline and postchemoradiation positron emission tomography changes were correlated with overall survival and the degree of pathologic response in the resected specimen. Their results showed that the degree of changes used as continuous variable produce the best estimate for survival compared to traditional dichotomized percent decrease.

    5. Genitourinary Disease
      You have free access to this content
      Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma (pages 5193–5201)

      David J. Gallagher, Matthew I. Milowsky, Alexia Iasonos, Fernando C. Maluf, Paul Russo, Guido Dalbagni, Machele S. Donat, Mary G. Boyle, Junting Zheng, Jamie Riches and Dean F. Bajorin

      Article first published online: 10 AUG 2009 | DOI: 10.1002/cncr.24570

      Adjuvant treatment with a 4-drug, sequential chemotherapy regimen failed to improve disease-specific survival in patients who had high-risk, extravesical urothelial cancer compared with the survival observed for contemporary controls who underwent surgery alone. The therapy was poorly tolerated, illustrating the difficulty in delivering intensive, postoperative chemotherapy to an older patient population in a timely manner.

    6. Hematologic Malignancies
      You have free access to this content
      The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities : How does it relate to the original lenalidomide experience in MDS? (pages 5202–5209)

      Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, Stefan Faderl, Carlos Bueso-Ramos, Lynne Abruzzo, Sherry Pierce, Jianqin Shan, Jean-Pierre Issa and Guillermo Garcia-Manero

      Article first published online: 18 AUG 2009 | DOI: 10.1002/cncr.24575

      The investigators reviewed 2743 patients with myelodysplastic syndrome (MDS). Two hundred eighty-seven (10%) patients had deletion 5q and 216 (8%) had monosomy 5 abnormalities. The median survival was 33 months with deletion 5q alone, 17 months with deletion 5q and 1 other abnormality, and only 6 months to 12 months with deletion 5q and 2 or more abnormalities or chromosome 7 abnormality. Only 93 patients (3.4% of total) had lower risk MDS and deletion 5q; their median survival was 29 months (2-year survival 60%). This study provided expectations of outcome in MDS subsets with deletion 5q and highlighted that most patients with deletion 5q have additional abnormalities and a worse prognosis than what was previously reported in the literature.

    7. You have free access to this content
      Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type (pages 5210–5217)

      Antonio Salar, Eva Domingo-Domenech, Cristina Estany, Miguel A. Canales, Fernando Gallardo, Octavio Servitje, Guadalupe Fraile and Carlos Montalbán

      Article first published online: 11 AUG 2009 | DOI: 10.1002/cncr.24605

      First-line systemic therapy with rituximab and fludarabine produced a high complete remission rate in both gastric and extragastric mucosa-associated lymphoma tissue (MALT) lymphoma, but patients with gastric MALT responded faster. This regimen had very good tolerability, but establishing the long-term benefit of this therapy will require continued follow-up.

    8. Lung Disease
      You have free access to this content
      Local recurrence after surgery for early stage lung cancer : An 11-year experience with 975 patients (pages 5218–5227)

      Chris R. Kelsey, Lawrence B. Marks, Donna Hollis, Jessica L. Hubbs, Neal E. Ready, Thomas A. D'Amico and Jessamy A. Boyd

      Article first published online: 11 AUG 2009 | DOI: 10.1002/cncr.24625

      Greater than half of recurrences after surgery for early stage nonsmall cell lung cancer involved local sites. Pathologic factors such as lymphovascular space invasion, stage, and histology may help distinguish patients those at highest risk.

    9. Melanoma
      You have free access to this content
      Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma (pages 5228–5236)

      John Glaspy, Michael B. Atkins, Jon M. Richards, Sanjiv S. Agarwala, Steven O'Day, Robert D. Knight, J. Ulf Jungnelius and Agop Y. Bedikian

      Article first published online: 2 SEP 2009 | DOI: 10.1002/cncr.24576

      This phase 2/3 study tested the safety and efficacy of lenalidomide for stage IV metastatic melanoma patients with refractory disease. A dose of 25 mg versus 5 mg oral lenalidomide was well tolerated, but it did not confer significant clinical benefits in tumor response, time to progression, or overall survival of these patients.

    10. Neuro-Oncology
      You have free access to this content
      Gender disparity in the rate of partner abandonment in patients with serious medical illness (pages 5237–5242)

      Michael J. Glantz, Marc C. Chamberlain, Qin Liu, Chung-Cheng Hsieh, Keith R. Edwards, Alixis Van Horn and Lawrence Recht

      Article first published online: 30 JUL 2009 | DOI: 10.1002/cncr.24577

      Life-threatening illness creates severe stress that may result in marital discord, separation, or divorce and may adversely impact treatment, quality of life, and survival. The results of the current study demonstrated that partner abandonment in patients with serious medical illness was most pronounced in men and affected both quality of care and life.

    11. Sarcoma
      You have free access to this content
      Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma (pages 5243–5250)

      Ayesha Abdeen, Alexander J. Chou, John H. Healey, Chand Khanna, Tanasa S. Osborne, Stephen M. Hewitt, Mimi Kim, Dan Wang, Karen Moody and Richard Gorlick

      Article first published online: 10 AUG 2009 | DOI: 10.1002/cncr.24562

      The current study suggested that the vascular endothelial growth factor pathway is a critical signaling pathway in osteogenic sarcoma. The data identified specific proteins within these pathways toward which future investigations should be directed to further clarify their prognostic potential.

    12. You have free access to this content
      The role of angiocidin in sarcomas (pages 5251–5262)

      Catherine Liebig, Jonathan A. Wilks, Barry W. Feig, Thomas N. Wang, Mariya Wilson, Ann V. Herdman and Daniel Albo

      Article first published online: 24 JUL 2009 | DOI: 10.1002/cncr.24568

      Angiocidin is a tumor-associated molecule that is emerging as a key mediator of tumor progression in epithelial malignancies. The authors demonstrated the role of angiocidin in promoting gelatinase up-regulation and tumor cell invasion in sarcomas and evaluated the potential use of angiocidin-inhibitory peptides in decreasing tumor cell invasion in these aggressive neoplasms.

    13. Discipline

      Disparities Research
      You have free access to this content
      Obesity as a predictor of adverse outcome across black and white race : Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database (pages 5263–5271)

      Jayakrishnan Jayachandran, Lionel L. Bañez, William J. Aronson, Martha K. Terris, Joseph C. Presti Jr., Christopher L. Amling, Christopher J. Kane, Stephen J. Freedland and the SEARCH Database Study Group

      Article first published online: 10 AUG 2009 | DOI: 10.1002/cncr.24571

      Although obesity is associated with increased risk of higher grade disease and prostate-specific antigen recurrence after radical prostatectomy, whether these associations vary by race is unknown. In this study, the authors observed that obesity did not appear to be more or less influential in 1 race than another but, rather, was identified as a risk factor for aggressive cancer regardless of race.

    14. Epidemiology
      You have free access to this content
      Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts (pages 5272–5283)

      James J. Dignam, Lan Huang, Lynn Ries, Marsha Reichman, Angela Mariotto and Eric Feuer

      Article first published online: 10 AUG 2009 | DOI: 10.1002/cncr.24617

      The authors evaluated the performance of relative survival and cause-specific survival based on death certificate with respect to accuracy in estimating breast cancer-specific survival. Relative survival accurately estimated breast cancer-specific survival in higher risk patients, while for low risk patients, death certificate-based estimates were more accurate.

    15. You have free access to this content
      Care of long-term cancer survivors : Physicians seen by Medicare enrollees surviving longer than 5 years (pages 5284–5295)

      Lori A. Pollack, Walter Adamache, A. Blythe Ryerson, Christie R. Eheman and Lisa C. Richardson

      Article first published online: 14 AUG 2009 | DOI: 10.1002/cncr.24624

      Surveillance, Epidemiology, and End Results and Medicare data were used to characterize the specialties of physicians who provided care for Medicare recipients diagnosed with cancer >5 years earlier. The results showed that less than half of long-term survivors continued to see oncology specialists annually, and that the percentage who did so declined with each year from diagnosis, whereas most survivors saw primary care providers, and the percentage who did so did not decline substantially.

    16. Medical Oncology
      You have free access to this content
      Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer (pages 5296–5308)

      Xianglin L. Du, Rui Xia, Chih-Chin Liu, Janice N. Cormier, Yan Xing, Dale Hardy, Wenyaw Chan and Keith Burau

      Article first published online: 11 AUG 2009 | DOI: 10.1002/cncr.24621

      Anthracycline-containing chemotherapy regimens were associated with an increased risk of congestive heart failure, cardiomyopathy, and cardiac dysrhythmias, but not significantly associated with ischemic heart disease or conduction disorders.

  6. Original Article

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. Discipline

      Medical Oncology
      You have free access to this content
      Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer (pages 5309–5318)

      Zhiqiang Meng, Peiying Yang, Yehua Shen, Wenying Bei, Ying Zhang, Yongqian Ge, Robert A. Newman, Lorenzo Cohen, Luming Liu, Bob Thornton, David Z. Chang, Zongxing Liao and Razelle Kurzrock

      Article first published online: 21 AUG 2009 | DOI: 10.1002/cncr.24602

      A pilot study was conducted, using a phase 1 trial design, of huachansu (a Chinese medicine that comes from dried toad venom from the skin glands of Bufo gargarizans or B. melanostictus) in patients with advanced cancer. There were no dose-limiting toxicities even at doses up to 8× higher than typically used in China; 6 patients had prolonged stable disease or minor tumor shrinkage.

  7. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    1. Discipline

      Medical Oncology
      You have free access to this content
      Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy (pages 5319–5328)

      Michelle Shayne, Eva Culakova, Debra Wolff, Marek S. Poniewierski, David C. Dale, Jeffrey Crawford and Gary H. Lyman

      Article first published online: 11 AUG 2009 | DOI: 10.1002/cncr.24560

      In this large prospective observational study that evaluated patient and treatment characteristics contributing to hematologic toxicity in breast cancer patients, there were no significant differences noted with regard to chemotherapy-related hematologic toxicities between older and younger patients treated with curative intent. Relative dose intensity of chemotherapy was significantly reduced for the older patients compared with their younger counterparts.

    2. Outcomes Research
      You have free access to this content
      An evaluation of lower-body functional limitations among long-term survivors of 11 different types of cancers (pages 5329–5338)

      Mario Schootman, Rebecca Aft and Donna B. Jeffe

      Article first published online: 12 AUG 2009 | DOI: 10.1002/cncr.24606

      The aim of this analysis was to identify factors associated with the increased prevalence of lower-body functional limitations by comparing long-term cancer survivors with persons without a cancer history (controls). Of long-term survivors of cancers, 57.0% reported being limited in ≥1 lower-body functional limitations, compared with 26.6% of controls. Arthritis, lower-back pain, and access to medical care can be targeted to reduce the prevalence of lower-body functional limitations and improve quality of life of long-term survivors of breast, cervical, ovarian, and uterine cancers, possibly with the aid of a survivorship care plan.

    3. Pediatric Oncology
      You have free access to this content
      Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma : A report from the Children's Oncology Group (pages 5339–5348)

      Alexander J. Chou, Eugenie S. Kleinerman, Mark D. Krailo, Zhengjia Chen, Donna L. Betcher, John H. Healey, Ernest U. Conrad III, Michael L. Nieder, Michael A. Weiner, Robert J. Wells, Richard B. Womer, Paul A. Meyers and on behalf of the Children's Oncology Group

      Article first published online: 27 JUL 2009 | DOI: 10.1002/cncr.24566

      For patients with metastatic osteosarcoma, the addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy did not lead to a statistically significant improvement in outcome. However, the pattern of event-free survival and overall survival benefit was similar to that seen in nonmetastatic osteosarcoma patients treated with liposomal MTP-PE, where overall survival was improved.

    4. Psychosocial Oncology
      You have free access to this content
      Depression as a predictor of disease progression and mortality in cancer patients : A Meta-Analysis (pages 5349–5361)

      Jillian R. Satin, Wolfgang Linden and Melanie J. Phillips

      Article first published online: 14 SEP 2009 | DOI: 10.1002/cncr.24561

      This meta-analysis revealed overall increased mortality of up to 25% in patients experiencing depressive symptoms after cancer diagnosis (risk ratio [RR] unadjusted = 1.25; 95% confidence interval [CI], 1.12 to 1.40; P < .001), and a 39% higher risk in patients diagnosed with major or minor depression after cancer diagnosis (RR unadjusted = 1.39; 95% CI, 1.03-1.89; P = .033), based on 25 independent studies. Given the scarce number of relevant studies available to date, the effect of depressive symptoms on cancer recurrence did not reach significance (RR unadjusted = 1.23; 95% CI, 0.85-1.77; P = .275, k = 3).

SEARCH

SEARCH BY CITATION